| Literature DB >> 32660560 |
Yan-Hui Li1, Tiecheng Yu2, Wenjing Shao3, Yanwei Liu2, Dong Zhu4, Lei Tan5.
Abstract
BACKGROUND: Intramedullary nails have become the main treatment for intertrochanteric fractures. However, a distal locking procedure during nailing gradually raised controversy. In this study, a systematic review and meta-analysis of clinical trials was performed to summarize existing evidence, aiming to determine the safety and efficacy of distal locking or unlocking in the nailing of stable intertrochanteric fractures.Entities:
Keywords: Intertrochanteric fracture; Intramedullary nails; Locked intramedullary nailing; Meta-analysis; Outcomes; Unlocked intramedullary nailing
Mesh:
Year: 2020 PMID: 32660560 PMCID: PMC7359611 DOI: 10.1186/s12891-020-03444-6
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Study flow diagram
Fig. 2Summary of the risk of bias of each included randomized controlled trial
Characteristics of the included studies
| Study | Year | Nation | Study design | Diagnosis characteristics (AO/OTA) | Implant | Gender (M/F) | Mean age (years) | Type of fracture (A1/A2/total, n) | Follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Locking | Locking | Unlocking | Unlocking | Locking | Unlocking | |||||||
| Ciaffa V | 2018 | Italy | RCT | 31-A1+ A2 | Citieffe nail | 89/50 | 77.1 ± 2.3 | 75.6 ± 3.5 | 49/24 | 46/93/139 | 25/48/73 | 12 |
| Lanzetti RM | 2018 | Italy | PCS | 31-A1+ A2 | SM Supernail | 11/57 | 84.5 ± 8.76 | 85.48 ± 7.84 | 13/62 | 38/30/68 | 35/40/75 | 14.1 (12–18). |
| Li X | 2015 | China | RCT | 31-A1 + A2 | PFNA-II | 11/24 | 78.1 ± 6.9 | 78.3 ± 7.0 | 10/25 | 7/28/35 | 11/24/35 | 12 |
| Lopez-Vega M | 2015 | Spain | RCT | 31-A1 + A2 | Gamma 3 nail | 17/73 | 84,59 ± 9,11 | 83,68 ± 6,90 | 19/68 | 34/56/90 | 46/41/87 | 12 |
| Skala-Rosenbaum | 2010 | Czech Republic | PCS | 31A1 + A2 | PFH | 10/34 | 79.6 | 79.8 | 17/57 | 14/30/44 | 38/36/74 | 12 |
| Skala-Rosenbaum J | 2016 | Czech Republic | PCS | 31A1 + A2 | PFN | N/A | N/A | 81.7 | 82.8 | NA/NA/595 | NA/NA /254 | 12 |
| V.Caiaffa | 2016 | Italy | RCT | 31-A1 + A2 | Citieffe nail | 41/89 | 78.4 ± 7.1 | 77.9 ± 7.2 | 52/84 | 37/93/130 | 48/88/136 | 12 |
| Vopat BG | 2014 | USA | RCS | 31-A1.1,+.2, +.3 | long Gamma3 | NA | NA | NA | NA | 56/0/56 | 51/0/56 | 12 |
| Yun, Ho Hyun | 2015 | Korea | RCS | 31-A1.1 + .2 | Gamma3 | 11/7 | 75.1 ± 11.7 | 75.1 ± 11.7 | 21/8 | 18/0/18 | 29/0/29 | 17.8 ± 10.6 |
RCT randomized controlled trial, PCS prospective cohort study, RCS retrospective cohort study, M/F male/female, NA notavailable
Quality Assessment of Included Cohort Studies Using the Newcastle-Ottawa Scale
| Lanzetti RM. 2018 [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Skala-Rosenbaum, 2010 [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Skala-Rosenbaum,2016 [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 |
| Vopat BG, 2014 [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Yun, Ho Hyun, 2015 [ | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 7 |
The quality of included studies was assessed by the Newcastle Ottawa scale. A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories and a maximum of two stars for Comparability
Selection: 1) Representativeness of exposed cohort: 1, study population truly or somewhat representative of a community/ population based study; 0, study population was sampled from a special population, that is, population from a company, hospital patients, data from the health insurance company or health examination organization, nurses
2) Selection of non-exposed cohort: 1, drawn from the same community as the exposed cohort
3) Ascertainment of exposure: 1, Validation of macrolides use with secure medical record; 0, no specific macrolides use validation method
4) Demonstration that outcome was not present at start of study: 1, exclusion of participants with a history of severe ventricular arrhythmia or sudden cardiac arrest at the beginning of the study
Comparability: 1) 1, whether a study adjusted for fracture type deliberately; 1, whether a study adjusted for other risk factors
Outcome: 1) Assessment of outcome: 1, events were confirmed by medical records or record linkage; 0, self-reported
2) Was follow-up long enough for outcomes to occur: 1, duration of follow-up > = 1 year; 0, if duration of follow-up < 1 year
3) Loss to follow-up rate: 1, complete follow-up or loss to follow up rate < =20%; 0, follow-up rate < 80% or no description of those lost
Fig. 3Comparison of the duration of operation, blood loss, patients transfused, and fluoroscopy time between the locking group and unlocking group. SD = standard deviation, IV = inverse variance, CI = confidence interval, and df = degrees of freedom
Postoperative comparison of LIN and ULN
| RCT subgroup | 2 | 261 | 73/258 | 50/190 | I2 = 0%, | 1.40 [0.90, 2.19] |
| Non-RCT subgroup | 2 | 448 | 20/112 | 21/149 | I2 = 0%, | 1.28 [0.65, 2.51] |
| Overall | 4 | 709 | 93/370 | 71/339 | I2 = 0%, | 1.36 [0.94, 1.98] |
| 3 | 537 | 11/298 | 8/239 | I2 = 0%, | 1.13 [0.44, 2.90] | |
| 3 | 537 | 3/298 | 2/239 | I2 = 0%, | 1.18 [0.22, 6.26] | |
| RCT subgroup | 4 | 714 | 6/388 | 3/326 | I2 = 0%, | 1.51 [0.37, 6.25] |
| Non-RCT subgroup | 4 | 415 | 2/186 | 1/229 | I2 = 41%, | 1.52 [0.26, 8.99] |
| Overall | 8 | 1129 | 8/574 | 4/555 | I2 = 0%, | 1.52 [0.50, 4.60] |
| RCT subgroup | 3 | 655 | 3/421 | 5/399 | I2 = 43%, | 0.66 [0.08, 5.76] |
| Non-RCT subgroup | 2 | 165 | 3/359 | 5/296 | N/A | N/A |
| Overall | 5 | 820 | 0/62 | 0/103 | I2 = 43%, | 0.66 [0.08, 5.76] |
| RCT subgroup | 4 | 714 | 6/388 | 8/326 | I2 = 60%, | 0.50 [0.06, 4.23] |
| Non-RCT subgroup | 4 | 1157 | 5/725 | 18/432 | I2 = 78%, | 0.73 [0.05, 11.03] |
| Overall | 8 | 1871 | 11/1113 | 26/758 | I2 = 69%, | 0.59 [0.11, 3.18] |
| 4 | 714 | 12/388 | 13/326 | I2 = 0%, | 0.76 [0.34, 1.67] | |
| 4 | 714 | 3/388 | 0/326 | N/A | 7.00 [0.36, 137.53] | |
| RCT subgroup | 4 | 714 | 5/388 | 3/326 | I2 = 41%, | 1.53 [0.43, 5.43] |
| Non-RCT subgroup | 3 | 308 | 0/130 | 1/178 | N/A | 0.51 [0.02, 13.29] |
| Overall | 7 | 1022 | 5/518 | 4/504 | I2 = 30%, | 1.30 [0.41, 4.13] |
| 3 | 272 | 0/298 | 1/239 | N/A | 0.35 [0.01, 8.57] | |
| RCT subgroup | 3 | 655 | 1/359 | 2/296 | I2 = 0%, | 0.41 [0.05, 3.30] |
| Non-RCT subgroup | 3 | 368 | 0/168 | 2/200 | I2 = 0%, | 0.40 [0.04, 3.93] |
| Overall | 6 | 1023 | 1/527 | 4/496 | I2 = 0%, | 0.41 [0.09, 1.90] |
| RCT subgroup | 3 | 502 | 49/249 | 16/253 | I2 = 63%, | 2.90 [0.97, 8.68] |
| Non-RCT subgroup | 3 | 272 | 7/118 | 6/154 | I2 = 20%, | 1.62 [0.37, 7.04] |
| Overall | 6 | 774 | 55/367 | 22/407 | I2 = 45%, | 2.45 [1.05, 5.73] |
Fig. 4Comparison of peri-implant fractures between the locking group and the unlocking group. SD = standard deviation, IV = inverse variance, CI = confidence interval, and df = degrees of freedom
Fig. 5Comparison of mortality between the locking group and the unlocking group. SD = standard deviation, IV = inverse variance, CI = confidence interval, and df = degrees of freedom
Function comparison of LIN and ULN
| 3 | 537 | N/A | N/A | I2 = 35%, | 0.14 [−1.33, 1.62] | |
| 4 | 714 | 242/388 | 224/326 | I2 = 82%, | 0.89 [0.68, 1.17] | |
| 3 | 537 | 61/298 | 50/239 | I2 = 0%, | 0.91 [0.65, 1.28] | |
| 3 | 537 | 22/298 | 18/239 | I2 = 0%, | 1.07 [0.55, 2.07] | |
| 4 | 714 | 71/388 | 49/326 | I2 = 0%, | 1.30 [0.94, 1.82] |